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Abstract
Impaired suppressive capacity of CD4
+CD25
+FOXP3
+ regulatory T cells (Treg) from peripheral blood of patients with
multiple sclerosis (MS) has been reported by multiple laboratories. It is, however, currently unresolved whether Treg
dysfunction in MS patients is limited to reduced control of peripheral T cell activation since most studies analyzed
peripheral blood samples only. Here, we assessed early active MS lesions in brain biopsies obtained from 16 patients with
MS by FOXP3 immunohistochemistry. In addition, we used six-color flow cytometry to determine numbers of Treg by
analysis of FOXP3/CD127 expression in peripheral blood and cerebrospinal fluid (CSF) of 17 treatment-naı ¨ve MS patients
as well as quantities of apoptosis sensitive CD45RO
hiCD95
hi cells in circulating and CSF Treg subsets. Absolute numbers of
FOXP3
+ and CD4
+ cells were rather low in MS brain lesions and Treg were not detectable in 30% of MS biopsies despite
t h ep r e s e n c eo fC D 4
+ cell infiltrates. In contrast, Treg were detectable in all CSF samples and Treg with a CD45RO
hiCD95
hi
phenotype previously shown to be highly apoptosis sensitive were found to be enriched in the CSF compared to
peripheral blood of MS patients. We suggest a hypothetical model of intracerebral elimination of Treg by CD95L-mediated
apoptosis within the MS lesion.
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Introduction
Multiple Sclerosis (MS) is considered a prototype autoimmune
disease. Analysis of the autoimmune response is predominantly
studied in peripheral blood of MS patients or carried out in animal
models which share some similarities with MS such as EAE. Since
potentially pathogenic autoreactive T cells are present in the
periphery of healthy individuals [1,2] loss of peripheral tolerance
mechanisms has been suggested as a prerequisite to allow
activation and migration of self-destructive inflammatory cells to
the target organ. Active suppression by natural FOXP3
+
regulatory T cells (Treg) maintains peripheral tolerance and
controls autoreactive T cells [3,4]. We and others have reported
that Treg derived from peripheral blood of MS patients are
functionally impaired [5–7] and that this Treg defect might - at
least in part - reflect the reduced presence of naive Treg in MS
compared to healthy individuals [8,9]. Whereas putative autore-
active T cells are thought to exhibit resistance towards apoptosis
[10–13] Treg from MS patients are highly sensitive to induction of
CD95L-mediated apoptotic cell death as we have shown
previously [14,15]. This phenotype is not MS-specific since Treg
from healthy donors exhibit similar apoptosis sensitivity and Treg
turned out to be the most short-lived cells among T cells
populations [15,16]. By six-color FACS analysis we have
previously identified apoptosis-prone Treg [14,17] allowing to
quantify this Treg subpopulation without further functional
testing. Moreover, we have validated these assays for MS patients
[6,15]. It is a drawback, however, that most studies of Treg in MS
patients are limited to the analysis of peripheral blood and do not
include material derived from cerebrospinal fluid or inflamed
brain tissue. Evidence from other diseases has revealed that Treg
do not only inhibit activation of autoreactive T cells in the
periphery but also actively suppress inflammation at the site of
organ destruction [18]. Our current knowledge on Treg in the
human CNS is sparse and nearly no data is available on natural
FOXP3
+ Treg distribution in the MS lesion [19].
Here, we studied the frequency of natural FOXP3
+ cells in
brain tissue derived from MS patients who underwent biopsy. We
detected FOXP3
+ cells in active lesions as well as in the
cerebrospinal fluid (CSF) of treatment-naive MS patients. Whereas
Treg frequencies were not decreased in the CSF compared to
Treg in peripheral blood, presence of FOXP3
+ cells in MS brain
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17988Figure 1. Prevalence of CD4
+ and FOXP3
+ cells in MS lesions. Brain biopsies of 16 MS patients were analyzed by immunohistochemistry for
the presence of CD4
+ and FOXP3
+ cells. Sections of each biopsy were stained with CD4 mAb, FOXP3 mAb or isotype control mAbs. Whole-slide
analysis by complete scanning of the section and computer-aided analysis of positive cells was performed. (A) Representative CD4
immunohistochemistry of MS lesion. Positive cells show red cell surface staining. Bar indicates mm scale in two different magnifications. Tissue
was hematoxylin counterstained prior to analysis. (B) Representative FOXP3 immunohistochemistry of MS lesion. Positive cells show brown nuclear
staining. Bar indicates mm scale in two different magnifications. Tissue was hematoxylin counterstained prior to analysis. (C) Number of patients with
CD4
+ T cells in the section (0% negative, 100% positive) and number of patients with FOXP3
+ cells in the analyzed section (31% negative with 69%
positive for FOXP3). (D) Number of patients grouped by their content of FOXP3
+ cells and CD4
+ cells respectively in the analyzed section: ‘‘-‘‘ indicates
FOXP3
+ T Cells in MS Lesions
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prone phenotype are markedly enriched in the CSF from MS
patients might explain this difference.
Results
Immunohistochemical analysis of FOXP3
+ cells in brain
lesions
Inflammatory demyelinating, biopsy-derived brain lesions from
16 MS patients were analyzed by immunohistochemistry for the
presence of Treg in MS lesions. We performed immunohisto-
chemistry for FOXP3
+ cells and CD4
+ cells of paraffin-embedded
tissue as previously established by our group [20,21]. The specifity
and sensitivity of the immunohistochemical procedure has been
validated by various controls before [20,21]. Sections of each
biopsy were stained with CD4 mAb (Fig. 1 A), FOXP3 mAb
(Fig. 1 B) or isotype control mAbs respectively. We established
whole-slide analysis by complete scanning of the section and
computer-aided analysis of positive cells. All sections from MS
lesions with inflammatory infiltrates studied here revealed CD4
positive cells in the lesion (Fig. 1 C). In contrast, FOXP3
+ cells
were less frequently detectable with more than 30% of patients
showing no presence of FOXP3
+ cells at all within the whole
section (Fig. 1 C, D). We repeated the staining for FOXP3 in
biopsies with sufficient amount of embedded material to confirm
this finding. FOXP3 positive cells were located both in
perivascular areas (Fig. 1 B) as well as in the brain parenchyma.
No clustering of FOXP3
+ cells was observed within the tissue. As
MS lesions show a broad histological spectrum of demyelinating
and inflammatory activity, we assessed whether the presence of
Treg was dependent on the underlying pathology. Our study
included lesions with early active demyelination allowing the
definition of the immunopathological subtype [22] as well as
lesions with inflammatory activity but lack of ongoing demyelin-
ation (inactive lesions). However, paucity of FOXP3
+ cells did not
depend on the activity of the analyzed subtype (Fig. 1 E).
Six-color FACS analysis of CSF-derived lymphocytes from
treatment-naı ¨ve MS patients
We and others have previously described reduction of Treg
inhibitory capacities ex vivo in MS [5–7]. We extended this study
and found that (i) frequencies of naı ¨ve Treg are critical for
suppressive activities measured in vitro and (ii) naive Treg were
reduced in numbers in the peripheral circulation of the MS
patients [8]. As we could not observe accumulation of FOXP3
+ T
cells in MS lesions we hypothesized that putative Treg might
exhibit an apoptosis-prone phenotype once they have entered the
CNS space and that rapid elimination of highly apoptosis-sensitive
Treg within the brain could explain the low numbers of Treg in
the MS lesion. We have recently described that MS-derived Treg
exhibit similarly high apoptosis sensitivity as Treg from healthy
controls [15]. Only Treg with high expression of CD45RO and
CD95 commit apoptosis when they bind cell surface CD95Ligand
[17].
Therefore, multicolor FACS analysis to determine
CD4
+CD25
+FOXP
+CD127
loCD45RO
hiCD95
hi cells allows us
to discriminate apoptosis-prone Treg from rather apoptosis-
resistant Treg with a more naı ¨ve phenotype [17]. To this end,
we pairwise isolated lymphocytes from CSF and PBMC and
stained isolated cells with monoclonal antibodies against CD4,
CD25, CD127, FOXP3, CD45RO and CD95 (Fig. 2). Multicolor
gating revealed that CD4
+CD25
+FOXP3
+ cells almost completely
overlap with CD4
+CD25
+CD127
lo cells as recently described
[23,24]. As shown in Fig. 2B CD4
+CD25
+CD127
lo cells constitute
a separate population. Backgating confirmed that nearly all cells
correspond to FOXP3
+ cells. Therefore, we included in some cases
of CSF samples with rather low cell counts the analysis of
CD4
+CD25
hiCD127
loCD45RO
hiCD95
hi cells in our study. When
we analyzed the percentage of CD95
hiCD45RO
hi Treg in a
cohort of 17 MS patients we found a significantly (p=0.019)
higher percentage of such apoptosis-prone Treg in CSF compared
to peripheral blood (Fig. 2C). Likewise, CD95 expression on CSF
derived Treg was higher than on Treg derived from peripheral
blood resulting into a higher percentage of CD95
hi Treg in CSF
(Fig. 3B). Functional analysis confirmed a high apoptosis sensitivity
of CSF-derived Treg towards CD95L-mediated apoptosis (data
not shown). As immunohistochemistry of brain biopsies revealed
reduced numbers of intralesional Treg (Fig. 1) we also compared
total Treg frequencies in CSF with Treg frequencies in peripheral
blood. Treg were present in all CSF samples analyzed. Moreover,
there was a clear tendency for higher Treg rates in CSF than in
peripheral blood (mean CSF 6.8% of CD4
+ cells vs. PBMC mean
4.8% of CD4
+ cells).
Migration of CD95
hi45RO
hi Treg towards CSF from
treatment-naı ¨ve MS patients
Alterations in migration properties of Treg could explain low
numbers of Treg in the active MS lesion. To address this question
we performed transwell migration experiments to analyze chemo-
taxis of Treg towards CSF from MS patients. We specifically
determined the migration capacity of CD95
hiCD45RO
hi
CD45RO
hi Treg versus its CD45RA
hi naı ¨ve counterpart. In
accordance with the accumulation of CD95
hiCD45RO
hiC-
D45RO
hi Treg in patient derived CSF, this subset exhibited a
significantly higher chemotactic activity (CI-CD45RA
loCD45RO
hi:
1.7160.53, CI-CD45RA
hiCD45RO
lo: 0.7460.24, p,0.001;
Fig. 4).
Discussion
Multiple sclerosis is associated with a functional defect of natural
Treg as we and others have reported [5–7]. Most studies are
limited to the analysis of peripheral blood and show no numeric
Treg abnormality but reduced in vitro suppressive capacity of
CD4
+CD25
hi Treg. However, Treg perform their inhibitory
function in the lymphoid and other target organs in vivo. We and
others could detect Treg accumulation at sites of inflammation in
several human inflammatory diseases [20,21], a process potentially
also initiated by cancer cells to attract Treg into human tumor
tissue [25]. However, no studies of Treg in early MS lesions from
brain biopsies of treatment-naı ¨ve patients with active MS are
currently available. Knowledge regarding quantities and pheno-
type of Treg in the CSF is also scarce. Previous analysis of Treg in
CSF was performed by detecting CD27
+ or CD25
hi cells [6,7,23]
but no data is available on the complete Treg population defined
by FOXP3 and CD127 expression levels and their detailed
phenotypic characterization is missing. Nevertheless, previous
studies of such ill-defined subpopulations show accumulation of
Treg in the CSF when compared to peripheral blood [7,23].
0 cells/mm
2, ‘‘(+)’’ 0-3 cells/mm
2,‘ ‘ +’’ .4-15 cells/mm
2,‘ ‘ ++’’ .15 cells/mm
2.( E) Number of patients with (+) or without detection of FOXP3
+ cells (-) in
active or inactive MS lesions.
doi:10.1371/journal.pone.0017988.g001
FOXP3
+ T Cells in MS Lesions
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17988Figure 2. Representative six-color FACS analysis of lymphocytes derived from CSF and peripheral blood. Isolated lymphocytes were
stained with monoclonal antibodies against CD4, CD25, CD127, FOXP3, CD45RO and CD95. CD4
+ cells were gated (G1) and analyzed for FOXP3,
CD127 and CD25 (A). CD4
+ cells are shown in all other dot plots of Fig. 2A, B in blue and represent 48% of peripheral lymphocytes. (B) CD4 positive
FOXP3
+ T Cells in MS Lesions
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+ T cells in
brain lesions derived from 16 RR-MS patients who underwent
brain biopsy. We detected FOXP3
+ T cells mainly in active
lesions. Further, Treg were abundant in the CSF of treatment-
naı ¨ve MS patients and our findings confirm the trend for
enhanced frequencies compared to peripheral blood within the
same patient (pairs from CSF and peripheral blood samples from
13 MS patients were analyzed, CSF samples were derived from
17 MS patients in total). Treg migrate easily into the CNS
compartment as we have previously published although extensive
proliferation of Treg in the CNS cannot be ruled out [26].
Similarly, other immunomodulatory T cells with expression of
HLA-G were reported to accumulate in the CSF [27]. These
observations are important, since novel drugs such as natalizumab
aim to inhibit the transfer of deleterious T cells into the CNS.
However, no data is available to clarify if application of such
agents might not only inhibit migration of autoreactive effector T
cells, but might also interfere with Treg migration into MS brain
lesions [28].
Whereas Treg rates showed a tendency for higher frequencies in
CSF when compared to Treg frequencies in peripheral blood,
FOXP3
+ T cells were hardly present in the MS brain lesion. 70%
percent of early MS lesions showed low FOXP3
+ T cell infiltration
in both perivascular areas and regions without blood vessels.
Clusters between FOXP3
+ and FOXP3
2 T cells were not
observed. FOXP3
+ cells were both present in regions with high
CD4 numbers as well as in regions with low CD4 numbers within
the MS lesion. In the remaining 30% of patients we were unable to
detect any FOXP3 positive cells, even in the presence of CD4
+
cells in the brain biopsies. A low number of FOXP3
+ T cells in the
MS lesion is in line with available data of post-mortem brain
material from 14 MS patients [19]. Although several groups show
CD4
+ infiltration as a typical feature of MS lesions [19,29–32]
FOXP3
+ cells were not detectable in any of the post mortem
specimens analyzed [19]. However, it cannot be ruled out that
post mortem brain material from MS patients with 10 or many
more years disease duration and/or immunomodulating therapy
might differ significantly from biopsies obtained from early MS
lesions from newly diagnosed treatment-naı ¨ve MS patients.
Determination of precise Treg frequencies within the MS lesion
appears rather problematic. Transient upregulation of FOXP3 in
non-regulatory T cells has been shown by several laboratories.
Moreover, multimarker analysis as used by flow cytometry cannot
be applied (i.e. CD127, CD62L, FOXP3, CD25, CD4) to detect
Treg by immunohistochemistry. FOXP3
+ Tcon are currently
thought to have a lower expression level of FOXP3 than Treg
[45]. Of note, immunohistochemical analysis of cell sorted CD4
+
subpopulations revealed that anti-FOXP3 immunohistochemistry
as used here did only detect CD4
+CD25
+ cells with high FOXP3
expression (data not shown). Therefore, when taking into account
the possibility of FOXP3
+ Tcon being present within lesions, Treg
frequencies might be even lower. This would strengthen our
hypothesis of Treg paucity in the MS lesion.
A low number of T cells with immunosuppressive function is not
a general feature of the human brain. Similar to EAE in mice Treg
accumulate in brain parenchyma surrounding human brain
tumors [33] and HLG
+ regulatory T cells detectable in MS
plaques [27]. We hypothesize that a dysregulated Treg homeo-
stasis might account for low intralesional Treg numbers in MS.
CD95L mediated apoptosis is a major mechanism to control Treg
numbers as we could show in a previous study [14,17]. Thymus-
derived naı ¨ve Treg are resistant towards CD95L mediated
apoptosis. Following Treg activation, cell surface expression of
CD95 is rapidly upregulated concomitantly with an increased
sensitivity towards CD95L mediated cell death. Such preactivated
Treg are apoptosis-prone and constitute the majority of CD25
hi-
FOXP3
+ Treg in the peripheral circulation of healthy adults. In
contrast to conventional T cells, Treg do not persist as apoptosis-
resistant memory cells. High apoptosis sensitivity renders Treg an
extremely short-lived population among T cells [16]. In vivo, Treg
seem even more sensitive than activated conventional T cells
towards CD95L [34–36]. Our previous studies of apoptosis
sensitivity from various Treg subpopulations revealed that Treg
with high expression of CD95 and CD45RO consistently die when
challenged with CD95L in vitro [14,15,17]. By analyzing the
percentage of these apoptosis-prone CD95
hiCD45RO
hi Treg in
MS patients we found a significant enrichment of these cells in
CSF (Fig. 3). Since we have previously shown that peripheral
blood Treg from treatment-naı ¨ve MS patients and healthy
individuals have a similar susceptibility to undergo apoptosis [6],
we exclude the possibility that genetic alterations might lead to an
altered apoptosis sensitivity of Treg in MS. Thus, we consider it
very likely that CD95
hiCD45RO
hi Treg of the CSF from MS
patients are highly apoptosis-prone. Functional analysis of the
whole CSF lymphocyte fraction confirmed a high apoptosis
sensitivity of CSF-derived Tregs towards CD95L-mediated
apoptosis (data not shown). In contrast, percentages of total
apoptotic cells in CSF were rather low. This coincided with low
numbers of recently activated Tcon expressing CD69 and CD38
(data not shown). In the MS lesion, expression levels of CD95L
and sensitivity towards CD95L mediated apoptosis might increase
after TCR restimulation. Interaction with non-immune cells might
further modify intralesional cell death rates. Elimination of Treg
by CD95L could occur not only by cell contact with CD95L
positive Tcon but also by contact with other CD95L expressing
CNS cells (i.e. endothelium) within the MS lesion. However, due
to very low numbers of FOXP3
+ T cells, we could not determine
cell death rates by immunohistochemistry.
Alterations in migration properties of Treg could also explain
low numbers of Treg in the active MS lesion. In vitro, human
Treg seem to migrate even faster than Tcon. Moreover, under
inflammatory conditions Treg from MS patients migrate to a
similar extent as Treg from healthy individuals [44]. Here, we
analyzed Treg migration towards CSF from MS patients with
active MS and did not observe a failure of Treg migration. Of
note, migration assays revealed, that CD95
hiCD45RO
hi Treg are
more strongly attracted by patient derived CSF compared to
CD45RA
hi Treg consistent with their accumulation in CSF during
disease activity.
In summary, we observe active migration of CD95
hiCD45RO
hi
Treg towards CSF of MS patients, accumulation of CD95
hiC-
D45RO
hi Treg in CSF and high apoptosis-sensitivity of CSF-
derived Treg from MS patients. We detect low numbers of
FOXP3 cells in MS lesions, but cannot proof enhanced
intralesional Treg elimination.
cells with significant FOXP3 expression and low to high CD25 expression were included in gate (G2). These cells are shown in all other dot plots of Fig.
2A, B in red and represent 7.1% of CD4 positive cells. Multicolor analysis confirms that the majority of FOXP3 positive cells co-segregate with
CD127
loCD25
lo-hi expression. Note: CD127 negative cells accumulate in the first few channels by conventional dot plotting. (C) Pairwise analysis from
CSF and PBMC of a treatment-naı ¨ve MS patient. Isolated lymphocytes were stained with monoclonal antibodies against CD4, CD25, CD127, FOXP3,
CD45RO and CD95. Lymphocytes were gated for CD4
+CD25
+CD127
loFOXP3
+ cells and the percentage of CD95
hiCD45RO
hi was determined.
doi:10.1371/journal.pone.0017988.g002
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17988In a hypothetical model we suggest (i) peripheral Treg activation
followed by (ii) migration into the cerebrovascular circulation.
Transmigration of Treg into MS lesions might be accompanied by
(iii) Treg restimulation of CNS cells with antigen presenting
function. Due to several rounds of TCR stimulation Treg are
sensitive to undergo apoptosis. Constant elimination of Treg in the
MS lesion could be the reason for the low numbers of intralesional
Treg in our study.
Several other factors might also render Treg susceptible to cell
deathintheautoimmunelesion,e.g.IL-2deprivation.Itwasrecently
demonstrated that Tregs inpancreatictissue of NOD mice areprone
to apoptosis because of insufficient levels of IL-2 [37]. Likewise, we
have shown previously that Treg are prone to Il-2 deprivation death
in MS [15]. Whether Il-2 levels are decreased in the MS lesion
remains to be determined. Collectively, we favor a model of
enhanced Tregturnover inthe target organduring activeMS,which
might influence the homeostatic composition of the Treg pool.
Our findings shed a new light on the initial finding of reduced
Treg inhibitory function in MS patients. Taking the available data
together the following picture emerges. The suppressive capacity
of the highly purified in vivo preactivated CD25
hiCD45RO
hi Treg
subpopulation is normal in RR-MS patients [8,9,38]. In contrast,
alterations within the naı ¨ve Treg pool possibly related to reduced
thymic output of naı ¨ve Treg in MS might explain the reduced
suppressive function initially observed in the total Treg population
in RR-MS [8,9]. Enhanced Treg turnover in the MS lesion as
reported here might further skew the balance of naı ¨ve and
activated Treg so that activated CD95
hiCD45RO
hi Treg become
the prevalent population.
Methods
Patients
The study included 33 patients (16 with CNS biopsy, 17 with
CSF samples) with definite relapsing remitting MS according to
the Poser criteria [39]. Brain biopsies from 16 patients with
histopathologically confirmed MS were obtained from the
Department of Neuropathology, University Medical Center
Go ¨ttingen. All patients underwent brain biopsy to rule out other
CNS diseases such as lymphoma, toxoplasmosis or vasculitis.
Patients: brain biopsies
By using conventional and immunocytochemical stainings each
MS case revealed characteristics of inflammatory demyelination of
the CNS consistent with Mutilpe Sclerosis [40,41]. The lesions
were then categorized according to their stage of demyelinating
activity [42]. Here, lesions with early active (EA) demyelination
show numerous infiltrating cells including foamy macrophages
containing myelin degradation products of all major myelin
proteins (MBP, PLP, MAG, MOG, CNPase). Inactive lesions (IA)
demonstrate complete demyelination, and macrophages do not
reveal signs of cytoplasmatic myelin protein degradation. However
inactive demyelinating lesions are still inflammatory active.
According to Lucchinetti and Bru ¨ck lesions with early active
demyelination reveal either of four different immunopathological
subtypes of multiple sclerosis, indicating pathogenetic heteroge-
neity [22]. Patterns (IP) I and II are characterized by a marked T
cell/macrophage-associated demyelination, with (IP II) or without
(IP I) additional immunoglobulin and complement depositions at
sites of active myelin destruction, respectively. These two patterns
belong to the so-called autoimmune-mediated subtypes. In
contrast pattern III and IV reveal marked oligodendropathology.
Here, pattern III lesions show signs of a distal oligodendroglio-
pathy with detection of apoptotic oligodendrocytes, and a distinct
loss of MAG or CNPase. Pattern IV, however, is a very rare
subtype which is restricted to primary progressive MS and
associated with primary oligodendrocyte degeneration.
In this study, 16 MS biopsies were enrolled. Eleven samples
revealed early active demyelination (four pattern I lesions, five
pattern II specimens, and two pattern III samples, but no pattern
IV biopsies). Five additional cases revealed inactivity with respect
to demyelination.
Patients: CSF and peripheral blood samples
CSF samples and peripheral blood specimens were derived
pairwise from 17 unrelated patients at the same day. All 17
Figure 3. Six-color FACS analysis of lymphocytes derived from CSF and peripheral blood. Analysis of CSF and PBMC from 17 treatment-
naı ¨ve MS patients. Isolated lymphocytes were stained with monoclonal antibodies against CD4, CD25, CD127, FOXP3, CD45RO and CD95. (A)
Lymphocytes were gated for Treg and the percentage of CD95
hiCD45RO
hi was determined. Treg were increased in CSF when compared to peripheral
blood, * indicates p,0.05. (B) Expression of CD95 on Treg from CSF and PBMC derived from the same MS patient on the same day, representative
figure.
doi:10.1371/journal.pone.0017988.g003
Figure 4. Chemotactic activities for CD45RA
hi Treg and
CD45RO
hi Treg subsets. Chemotactic indices (CI) of Treg from a
healthy donor towards CSF supernatants of 11 MS patients as
determined by transwell migration assays. Original input PBMC and
migrated cells were stained for CD4, CD25, FOXP3, CD95, CD45RO, and
CD45RA, and CIs were calculated by dividing percentages of Treg
subsets in CD4
+ T-cells of migrated cells by percentages of Treg in CD4
+
T-cells in original input PBMCs. Symbols indicate CIs of individual
patients. Means are indicated, ** indicates p,0.001.
doi:10.1371/journal.pone.0017988.g004
FOXP3
+ T Cells in MS Lesions
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McDonald or Poser criteria [39,43], had clinically active disease
and had not yet received treatment with corticosteroids or
immunomodulatory agents. Patients had mean disease duration
of 14 months, a mean Expanded Disability Status Score (EDSS) of
2.4, and had previously experienced an average of two relapses.
The protocol was approved by the University of Heidelberg ethics
committee and all individuals gave written informed consent.
Antibodies and reagents
The monoclonal antibody (mAb) against CD4, CD127,
CD45RO, CD95 and isotype controls were obtained from BD
Pharmingen (Heidelberg, Germany), aCD25 mAb from Miltenyi
Biotech (Auburn, CA) and aFOXP3 mAb (clone 236A/E7) from
eBioscience (San Diego, USA).
Immunohistochemistry
Brain biopsies were fixed in 4% paraformaldehyde and
embedded in paraffin. Hematoxylin and eosin (H&E), CD4,
FOXP3 and mouse IgG1 isotype control stainings were performed
as previously described by our group [20,21]. Whole slide analysis
was performed with an aperio scanner to allow computer-aided
analysis of the sections. All specimens were blinded and analyzed
by two independent investigators. Standardized analysis was
performed.
Six-color FACS analysis
In most cases (13 pairs) pairwise analysis of peripheral blood
derived lymphocytes and CSF-derived lymphocytes was per-
formed. Lymphocyte preparation, immunostaining and FACS
analysis were carried out immediately after clinical sample
acquisition to prevent preanalytic alterations. To this end,
peripheral blood mononuclear cells (PBMCs) were obtained from
20 ml EDTA-blood by density gradient centrifugation using
Ficoll/Hypaque (Biochrom, Berlin, Germany). Likewise, 0.5 to
4 ml CSF was centrifuged to isolate mononuclear cells. Cells were
stained with monoclonal antibodies (mAb) against CD4, CD127,
CD45RO, CD95, CD25 and FOXP3 or isotype control mAbs
and FACS analysis was performed at a LSR II flow cytometer as
previously described [17,21]. Freezing and thawing was avoided
since control experiments showed significant alterations in
CD95
hiCD45RO
hi cell numbers when cells were stored in the
freezer previous to immunostaining (data not shown).
Migration assay
Migration activities of Treg subsets were assessed by using a
transwell assay as previously described [26]. In short, 10
6 freshly
isolated PBMCs obtained from one healthy standard donor were
suspended in 200 ml RPMI and transferred into the upper
chambers of 6.5-mm diameter, 5.0 mm pore-size polycarbonate
membrane filter transwell plates (Costar Corning, Cambridge,
MA). CSF supernatants were added to the lower chamber. After
4 hours at 37uC, migrated cells were collected and FACS-
analyzed. Chemotactic indices (CI) were defined as the ratio of
percentages of the distinct Treg subpopulation in migrated
PBMCs and of original PBMCs.
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